Table 1.
Active combinatorial trials in gynecologic cancers.
| Trial ID | Cancer | PARP inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|
| NCT03101280 | Ovarian + Endometrial | Rucaparib | Atezolizumab (PD-1) | I |
| NCT02571725 | gBRCA ovarian | Olaparib | Tremelimumab (CTLA-4) | I/II |
| NCT02953457 | •Ovarian •Fallopian tube •Peritoneal |
Olaparib | Tremelimumab (CTLA-4) | I/II |
| NCT03572478 | Recurrent Endometrial | Rucaparib | Nivolumab (PD-1) | I/II |
| NCT02660034 | gBRCA Ovarian | BGB-290 | BGB-A317 (PD-1) | I/II |
| NCT02657889 | •Ovarian, •Fallopian tube •Peritoneal |
Niraparib | Pembrolizumab (PD-1) | I/II |
| NCT02734004 | Ovarian | Olaparib | Durvalumab (PD-L1) +/- bevacizumab | I/II |
| NCT02484404 | •Ovarian, •Fallopian tube •Peritoneal |
Olaparib | Atezolizumab (PD-L1) cediranib (VEGFR) | II |
| NCT03330405 | Ovarian | Talazoparib | Avelumab (PD-1) | II |
| NCT03602859 | Ovarian | Niraparib | TSR-042 (PD-1) | II |
| NCT03574779 | Recurrent Ovarian | Niraparib | TSR-042 (PD-1) | II |
| NCT03955471 | PLR Ovarian | Niraparib | TSR-042 (PD-1) | II |
| NCT03824704 | •Ovarian, •Fallopian tube •Peritoneal •Serous Carcinoma |
Rucaparib | Nivolumab (PD-1) | |
| NCT03574779 | Ovarian | Niraparib | TSR-042 (PD-1) + bevacizumab | II |
| NCT02873962 | •Ovarian, •Fallopian tube •Peritoneal |
Rucaparib | Nivolumab (PD-1) + bevacizumab | II |
| NCT03694262 | •Endometrial •Carcinosarcoma |
Rucaparib | Atezolizumab (PD-1) + bevacizumab | II |
| NCT03651206 | Carcinosarcoma | Niraparib | TSR-042 (PD-1) | II/III |
| NCT03737643 | Ovarian (Maintenance) | Olaparib | Durvalumab (PD-L1) + bevacizumab | III |
| NCT03642132 | Ovarian | Talazoparib | Avelumab (PD-1) | III |
| NCT03598270 | Ovarian | Niraparib | Atezolizumab (PD-L1) + carboplatin | III |
gBRCA, germline BRCA mutation; PLR, platinum-resistant.